Clinical trials
Drug Susceptible Pulmonary Tuberculosis clinical trials
Below are recruiting drug susceptible pulmonary tuberculosis clinical trials, each written for real people, not researchers. We’re tracking 13 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07525427RecruitingPhase 2
New Tuberculosis Drug Study for Drug-Sensitive TB
This study tests a new tuberculosis drug called TBD09 combined with other TB medicines in people with newly diagnosed, drug-sensitive TB. The goal is to see if this combination works well and is safe.
Durban, BluffAges 18–65 - NCT07387601Recruiting
Peer education for TB treatment in Ethiopia
This trial tests whether having a peer educator (someone who has been through TB treatment) help you stay on track with your medicines and get better. It is for adults with new, easy-to-treat TB in South Omo and Ari Zone, Ethiopia.
Jinka, Southern EthiopiaAges 18 years+ - NCT04260477RecruitingPhase 3
Testing a new stronger TB retreatment medicine schedule
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
NiameyAges Any age - NCT05824871RecruitingPhase 3
Oral drug for rifampicin-resistant lung tuberculosis
This Phase 3 trial tests an oral medicine (Sudapyridine/WX-081) to treat people with rifampicin-resistant pulmonary tuberculosis. It compares how well the study drug works when you stop prior tuberculosis medicines and go through a short “washout” period first.
Beijing, Beijing MunicipalityAges 18–65 - NCT06192160RecruitingPhase 2
New TB drug combinations for drug-sensitive lung TB
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
GaboroneAges 18 years+ - NCT06199921RecruitingPhase 2
Atorvastatin plus TB treatment for new tuberculosis
This study tests whether adding the cholesterol drug atorvastatin to standard TB treatment helps people recover faster. It is for people with newly diagnosed, drug-sensitive tuberculosis who have not yet started treatment.
Zaria, Kaduna StateAges 12–65 - NCT06253715RecruitingPhase 3
Shorter TB treatment for children
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
ChennaiAges birth–9 years - NCT06441006RecruitingPhase 2/Phase 3
Personalized treatment for rifampicin-resistant TB
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
UlaanbaatarAges 14 years+ - NCT05807399RecruitingPhase 2
Step2c trial for new, drug-susceptible lung TB
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
LambarénéAges 18–65 - NCT07170800RecruitingPhase 2
Study of JDB0131 for drug-resistant TB
This trial tests a new tablet called JDB0131 for people with tuberculosis (TB) that is resistant to the antibiotic rifampicin. The goal is to see if it can effectively treat this hard-to-treat form of TB.
Wuhan, HubeiAges 14 years+ - NCT06526221Enrolling by invitation
Urine test to check TB medication use
This study checks a simple urine test to see if people with TB are taking their medication (isoniazid) regularly. It aims to help doctors find out sooner if someone is missing doses, so they can offer extra support.
Chennai, Tamil NaduAges 18 years+ - NCT06477185RecruitingPhase 2
Preventing lung scarring after TB with doxycycline
This trial tests whether the antibiotic doxycycline can prevent lung scarring (fibrosis) after a serious TB infection. You may be eligible if you are currently being treated for active TB and have significant lung damage on your chest X-ray.
Kampala, KampalaAges 18–65 - NCT07073638RecruitingPhase 2
Testing a new TB drug called RESP30TB in people with newly diagnosed TB
This trial tests a new drug, RESP30TB, to see if it is safe, tolerable, and can quickly kill TB bacteria in people with newly diagnosed, rifampicin-susceptible pulmonary TB. You may be eligible if you can produce sputum and meet other health criteria.
Cape Town, BellvilleAges 18–65
Hear when a new Drug Susceptible Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for drug susceptible pulmonary tuberculosis?
- Yes. Clin2 currently lists 13 recruiting drug susceptible pulmonary tuberculosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a drug susceptible pulmonary tuberculosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a drug susceptible pulmonary tuberculosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.